Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Latigo Biotherapeutics announced its second quarter 2026 results along with key business milestones including an upsized IPO that raised $397.4 million gross proceeds, publication of positive Phase 2 trial results of onzotrigine in The New England Journal of Medicine, and initiation of Phase 3 clinical trials. The company also appointed Naomi Lowy,…